HomeCompareSLMAF vs PFE

SLMAF vs PFE: Dividend Comparison 2026

SLMAF yields 3.66% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SLMAF wins by $1137.13M in total portfolio value
10 years
SLMAF
SLMAF
● Live price
3.66%
Share price
$6.58
Annual div
$0.24
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1137.18M
Annual income
$1,080,502,630.72
Full SLMAF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SLMAF vs PFE

📍 SLMAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSLMAFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SLMAF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SLMAF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SLMAF
Annual income on $10K today (after 15% tax)
$311.32/yr
After 10yr DRIP, annual income (after tax)
$918,427,236.11/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, SLMAF beats the other by $918,404,916.21/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SLMAF + PFE for your $10,000?

SLMAF: 50%PFE: 50%
100% PFE50/50100% SLMAF
Portfolio after 10yr
$568.61M
Annual income
$540,264,444.72/yr
Blended yield
95.01%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SLMAF
No analyst data
Altman Z
0.8
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SLMAF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSLMAFPFE
Forward yield3.66%6.13%
Annual dividend / share$0.24$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$1137.18M$49.6K
Annual income after 10y$1,080,502,630.72$26,258.71
Total dividends collected$1133.08M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SLMAF vs PFE ($10,000, DRIP)

YearSLMAF PortfolioSLMAF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,433$732.52$9,153$693.39+$2.3KSLMAF
2$13,798$1,565.34$8,593$849.25+$5.2KSLMAF
3$18,295$3,531.30$8,336$1,066.78+$10.0KSLMAF
4$28,328$8,751.84$8,437$1,384.80+$19.9KSLMAF
5$55,640$25,329.07$9,013$1,875.40+$46.6KSLMAF
6$152,525$92,990.40$10,306$2,680.72+$142.2KSLMAF
7$639,676$476,474.39$12,820$4,101.38+$626.9KSLMAF
8$4,419,576$3,735,122.45$17,673$6,826.70+$4.40MSLMAF
9$52,964,969$48,236,022.69$27,543$12,591.86+$52.94MSLMAF
10$1,137,175,148$1,080,502,630.72$49,560$26,258.71+$1137.13MSLMAF

SLMAF vs PFE: Complete Analysis 2026

SLMAFStock

Sanlam Limited provides various financial solutions to individual, business, and institutional clients in South Africa, rest of Africa, and internationally. The company operates through Sanlam Life and Savings, Sanlam Emerging Markets, Sanlam Investment Group, and Santam segments. It offers life, disability, severe illness, income protection, funeral, credit life, health, short-term, medical, and group risk benefits, business debt, commercial insurance products; reinsurance products; financial planning and retirement, personal motor and property, solutions; investment products; wealth, and professionals and graduates insurance services; and personal and home loans, and credit cards. The company also provides payment and debit cards order collection, corporate credit, debt and equity structuring, business advice, risk management, and employee health and retirement plans for small and medium businesses, and self-employed professionals. The company was founded in 1918 and is headquartered in Bellville, South Africa.

Full SLMAF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SLMAF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SLMAF vs SCHDSLMAF vs JEPISLMAF vs OSLMAF vs KOSLMAF vs MAINSLMAF vs JNJSLMAF vs MRKSLMAF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.